Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gaucher Disease, Type 2”

112 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 112 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03373097
What this trial is testing

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Who this might be right for
NeuroblastomaNeuroblastoma RecurrentGD2-positive Solid Tumors+3 more
Bambino Gesù Hospital and Research Institute 42
Testing effectiveness (Phase 2)Looking for participantsNCT07502287
What this trial is testing

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Who this might be right for
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-Risk Neuroblastoma+1 more
Beijing Biotech 36
Early research (Phase 1)Study completedNCT00085930
What this trial is testing

Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients

Who this might be right for
Neuroblastoma
Baylor College of Medicine 19
Early research (Phase 1)Study completedNCT00492167
What this trial is testing

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 45
Early research (Phase 1)Ended earlyNCT01123304
What this trial is testing

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Who this might be right for
Melanoma
Morphotek 18
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06948994
What this trial is testing

A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

Who this might be right for
NeuroblastomaGD2 AntibodyAutologous NK Cell
Guangzhou Women and Children's Medical Center 15
Testing effectiveness (Phase 2)UnknownNCT02173093
What this trial is testing

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Who this might be right for
Disseminated NeuroblastomaRecurrent Neuroblastoma
University of Virginia 40
Testing effectiveness (Phase 2)UnknownNCT05447494
What this trial is testing

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Who this might be right for
Gaucher Disease, Type 1Gaucher Disease, Type 3
CANbridge (Suzhou) Bio-pharma Co., Ltd. 40
Not applicableStudy completedNCT04470713
What this trial is testing

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2

Who this might be right for
GM1 GangliosidosisGM2 GangliosidosisGaucher Disease, Type 2+3 more
Idorsia Pharmaceuticals Ltd. 226
Not applicableStudy completedNCT02100930
What this trial is testing

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 69
Not applicableUnknownNCT02605603
What this trial is testing

SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease

Who this might be right for
Gaucher Disease
Lysosomal and Rare Disorders Research and Treatment Center, Inc. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04430595
What this trial is testing

Multi-4SCAR-T Therapy Targeting Breast Cancer

Who this might be right for
Breast Cancer
Shenzhen Geno-Immune Medical Institute 100
Large-scale testing (Phase 3)Looking for participantsNCT06669013
What this trial is testing

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaEmbryonal RhabdomyosarcomaAlveolar Rhabdomyosarcoma
N.N. Petrov National Medical Research Center of Oncology 40
Early research (Phase 1)Study completedNCT02482532
What this trial is testing

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

Who this might be right for
Melanoma
Gary Doolittle 7
Not applicableLooking for participantsNCT06574698
What this trial is testing

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Who this might be right for
NeuroblastomaGD2 Antibody (Naxitamab)
Guangzhou Women and Children's Medical Center 64
Testing effectiveness (Phase 2)Looking for participantsNCT06450041
What this trial is testing

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 62
Early research (Phase 1)Study completedNCT00037011
What this trial is testing

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center
Not applicableStudy completedNCT00597272
What this trial is testing

Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 34
Not applicableStudy completedNCT01418495
What this trial is testing

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Who this might be right for
Localized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeurotoxicity Syndrome+4 more
National Cancer Institute (NCI) 12
Post-approval studies (Phase 4)Study completedNCT00364858
What this trial is testing

Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

Who this might be right for
Gaucher Disease, Type 1Cerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease+2 more
Genzyme, a Sanofi Company 95
Next Page